To date, four CD19-redirected CAR-T products have been granted the US FDA approval for the treatment of certain patients, which highlights the potential applicability of this cancer treatment modality and the suitability of CD19 as a target antigen for the treatment of CD19-positive malignancies. Here, CD19 is linked to cancer.